The Wellcome Trust has awarded £4.7 million (€5.8 million) to EMBL’s European Bioinformatics Institute (EMBL-EBI) to support the transfer of a large collection of information on the properties and activities of drugs and a large set of drug-like small molecules from publicly listed company Galapagos NV to the public domain.
It will be incorporated into the EMBL-EBI’s collection of open-access data resources for biomedical research and will be maintained by a newly established team of scientists at the EMBL-EBI. These data lie at the heart of translating information from the human genome into successful new drugs in the clinic.
The human genome sequence provided a molecular ‘parts list’ for a human being, comprising all the genes and proteins that are encoded by our genetic blueprint. But to develop new medicines, it is important to catalogue how each of these ‘parts’ interacts with drugs and drug-like molecules. This interface of the genome with chemistry is a core part of the new scientific area of chemogenomics.
For the past eight years, researchers at BioFocus DPI, the service division of Galapagos, have been integrating the existing collections of information in these two areas to develop a set of well-structured chemogenomic databases that can be used to help determine whether a particular molecule has the right properties to make an effective drug. BioFocus DPI licensed this information to pharmaceutical and biotech companies worldwide. As part of the Wellcome Trust grant announced today, the EBI will obtain the rights to the databases from BioFocus DPI. The award will make it possible to provide free access to this information for all researchers. “The scientific community worldwide will greatly benefit from unrestricted access to these data.
It will aid their efforts in predictive drug discovery,” says Galapagos CEO Onno van de Stolpe. “Galapagos has successfully accelerated its research programmes with these, and BioFocus DPI used the data to deliver on its contracts with customers. After this transfer, which we hope will contribute to the advancement of drug discovery research by improving access to the data that we have collected, we will continue to use these resources.”
The transfer will empower academia to participate in the first stages of drug discovery for all therapeutic areas, including major diseases of the developing world. In future it could also result in improved prediction of drug side-effects. “We are excited to be able to provide information that defines the effects of a large number of small molecules on the body, and link this to the proteins that these molecules interact with, as part of our mission to provide wide access to bioinformatics tools to promote scientific progress and disseminate cutting-edge technologies to industry,” says EMBL-EBI Director Janet Thornton. “With this transfer, we aim to facilitate faster and better drug discovery. It speaks to the importance of this information for translational research that the Wellcome Trust has chosen to support this particular transfer with sufficient long-term funding.”
This unprecedented transfer of pharmaceutical data resources from the private sector to the public domain will have the greatest impact on researchers in academia and in small companies on limited budgets. “The Wellcome Trust has a strong commitment to making vital research tools freely available to the academic research community,” says Dr Alan Schafer, Head of Molecular and Physiological Sciences at theWellcome Trust. “Enabling these previously proprietary data to enter the public domain will allow researchers worldwide to make free use of knowledge essential for drug discovery.
Cath Brooksbank | alfa
Decoding cell communication
13.06.2019 | Friedrich-Alexander-Universität Erlangen-Nürnberg
ESJET printing technology for large area active devices awarded
11.04.2019 | Fraunhofer-Institut für Angewandte Polymerforschung IAP
The well-known representation of chemical elements is just one example of how objects can be arranged and classified
The periodic table of elements that most chemistry books depict is only one special case. This tabular overview of the chemical elements, which goes back to...
Light can be used not only to measure materials’ properties, but also to change them. Especially interesting are those cases in which the function of a material can be modified, such as its ability to conduct electricity or to store information in its magnetic state. A team led by Andrea Cavalleri from the Max Planck Institute for the Structure and Dynamics of Matter in Hamburg used terahertz frequency light pulses to transform a non-ferroelectric material into a ferroelectric one.
Ferroelectricity is a state in which the constituent lattice “looks” in one specific direction, forming a macroscopic electrical polarisation. The ability to...
Researchers at TU Graz calculate the most accurate gravity field determination of the Earth using 1.16 billion satellite measurements. This yields valuable knowledge for climate research.
The Earth’s gravity fluctuates from place to place. Geodesists use this phenomenon to observe geodynamic and climatological processes. Using...
Discovery by Brazilian and US researchers could change the classification of two species, which appear more akin to jellyfish than was thought.
The tube anemone Isarachnanthus nocturnus is only 15 cm long but has the largest mitochondrial genome of any animal sequenced to date, with 80,923 base pairs....
Researchers at Chalmers University of Technology, Sweden, have discovered a completely new way of capturing, amplifying and linking light to matter at the nanolevel. Using a tiny box, built from stacked atomically thin material, they have succeeded in creating a type of feedback loop in which light and matter become one. The discovery, which was recently published in Nature Nanotechnology, opens up new possibilities in the world of nanophotonics.
Photonics is concerned with various means of using light. Fibre-optic communication is an example of photonics, as is the technology behind photodetectors and...
29.04.2019 | Event News
17.04.2019 | Event News
15.04.2019 | Event News
18.06.2019 | Life Sciences
18.06.2019 | Life Sciences
18.06.2019 | Life Sciences